Beta Cell Therapy in Diabetes

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage, inaccessibility of the implants, risks of associated immunosuppression.

Short name and number: 
BetaCellTherapy (241883)
Name of US Partner: 
NOVOCELL INC
Contact: 

VRIJE UNIVERSITEIT BRUSSEL
center@betacelltherapy.org

Participating Countries: 
Italy
Norway
Switzerland
United Kingdom
United States
Area: 

Health

Category: 

FP7 Project with U.S. partner